Metabolic Research Peptides
Compounds in this category are studied for their activity at incretin receptors — principally GLP-1, GIP, and glucagon receptor pathways — and their downstream effects on glucose regulation and energy metabolism in preclinical models. This is the most heavily published area of peptide research in the last decade.
Semaglutide
5–20mg · COA published
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
- CAS
- 910463-68-2
- MW
- 4113.58
- Purity
- Per published certificate
Tirzepatide
10–30mg · COA published
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
- CAS
- 2023788-19-2
- MW
- 4813.45
- Purity
- Per published certificate
Retatrutide
10–30mg · COA published
Triple agonist at GIP, GLP-1, and glucagon receptors — among the most actively studied compounds in current metabolic research.
- CAS
- 2381089-83-2
- MW
- 4731.32
- Purity
- Per published certificate
Cagrilintide
10mg · COA published
Long-acting amylin analog studied at calcitonin and amylin receptors — a satiety pathway mechanistically distinct from incretin agonism.
- CAS
- 1415456-99-3
- MW
- 4409
- Purity
- Per published certificate
AOD-9604
5mg · COA published
C-terminal fragment of human growth hormone studied for lipolytic activity without the growth-promoting effects of the full hormone.
- CAS
- 221231-10-3
- MW
- 1815.08
- Purity
- Per published certificate
Direct comparisons in this area
Shortlisting within a research area is where most of these decisions actually get made, so the pairs are compared on the same measured figures rather than on claims.
Cagrilintide vs Semaglutide
Amylin versus incretin signaling — mechanistically independent satiety pathways, which is why they appear together in combination studies.
Semaglutide vs Retatrutide
The two ends of the incretin design space: a selective GLP-1 analog against a triple agonist.
Tirzepatide vs Retatrutide
Dual versus triple agonism. The question is what glucagon receptor activation adds beyond incretin signaling.
Semaglutide vs Tirzepatide
Single versus dual incretin receptor engagement — the central comparison in current metabolic pharmacology.
AOD-9604 vs Cagrilintide
AOD-9604 vs Retatrutide
Other research areas